
I’m delighted to share our latest paper — and my first as lead author: Restoring Homeodynamics: Autophagy, Ageing and the Metabolic Correction of Disease techscience.com/biocell/onli…

Long term brain cancer survivor, writer, researcher. Interest in metabolic therapies. Follow @cancermetstudy for more info.

I’m delighted to share our latest paper — and my first as lead author: Restoring Homeodynamics: Autophagy, Ageing and the Metabolic Correction of Disease techscience.com/biocell/onli…

I'm hosting an informal online Q&A on focused ultrasound and its potential applications in brain cancer this Thursday (19 November) at 9:30am UK time. If you'd like to attend, please message me privately with a little about yourself and why you'd like to join.

📢To everyone who eats a LOW-CARB, HIGH-FAT diet, please know: When a media headline says "high-fat diet does X terrible thing," e.g. "increase[s] colon cancer risk." This is often the diet they're talking about: Mice fed blue sludge made of soybean oil, lard, and sucrose. That is all. Repost with a funny comment if you're disturbed 🔄🤢

Today at Ketogenic Dietary Therapies 2026 in Salzburg, Keto-Mojo’s Cristina Fante, PhD, explored practical insights for bringing ketone testing into daily routine. Because success on a ketogenic diet isn’t defined by hitting a fixed carb limit, but by how an individual actually responds. Measuring ketones regularly makes that response visible to both practitioners and patients, helping to personalize treatment and empower people to take an active role in their own care. This matters because adherence is one of the biggest challenges in long-term therapies, particularly lifestyle interventions. But ketogenic metabolic therapy has an advantage: nutritional ketosis is a measurable state, so adherence can be monitored and acted upon. Watch a clip from Cristina's presentation👇 #KetoMojo #KetoMed #KetogenicTherapies #MetabolicHealth #KetoMed2026 #KDT2026

What a day at KDT 2026 in Salzburg, with more to come tomorrow! Great to finally meet neurosurgeon Dr Kris Smith, who presented findings from a study of 64 patients with high-grade gliomas treated with ketogenic metabolic therapy, including long-term follow-up.

I've worn CGMs on and off for years. Few tools are more insightful for understanding how food affects glucose, arguably our most important metabolic biomarker. Fascinating new @Levels preprint analyzing 62,000+ adults. Key takeaways: -Normal A1c can miss early insulin resistance. Elevated fasting insulin was ~2× as common with average glucose ≥110 mg/dL. -Average glucose tracks metabolic health better than A1c alone. -Just ~7 days of CGM provides a useful baseline. -Spike duration matters more than peak. -Test foods repeatedly (~5x) before drawing conclusions. Promising evidence for CGM's role in preventive health, not just diabetes management. Great work @paul_ginart and @michaelloesche!
Very exciting initial preprint illustrating Levels' unparalleled IRB-approved study. The study ran for 3.5 years and included more than 62,000 participants with multi-modal supplemental data alongside CGM. Among the early findings are strong indications that CGM is particularly informative about insulin resistance *before* a1c thresholds like prediabetes are hit. Kudos to Drs. @paul_ginart and Michael Loesche! Link to the MedRxiv preprint below

Brain cancer, epilepsy and the ageing brain, by @ascarbs andrewscarborough.substack.c…

Stephen Moore’s Post  Stephen Moore 4d Made in America. Banned in America. Let me tell you about a remarkable young woman named Braelyn. She was diagnosed with brain cancer at 16. Today she's 19, and her scans are clear. The treatment that got her there was invented by an American company, with American science and American ingenuity. Here's the outrage: Braelyn can't get it here. She has to travel to the UK for treatment. Think about that. We lead the world in medical innovation, and then we make our own citizens leave the country to benefit from it. The British are getting American breakthroughs that Americans can't. That isn't a free market. That's a regulatory roadblock, and it costs lives. President Trump understood this when he signed Right to Try in 2018. The idea was simple: if you're facing a life-threatening diagnosis, Washington shouldn't stand between you and a treatment that might save you. It was one of the best things he did in his first term. But Braelyn's story tells me the job isn't finished. The promise of Right to Try still isn't reaching the patients who need it most. When the President came to Clemson, South Carolina, for a rally near Braelyn's home, our team made sure she was there. Braelyn got her moment with the President, and he heard her story. Now it's Washington's turn. Make Right to Try work the way it was meant to. Put American cancer vaccine breakthroughs in the NCI Cancer Vaccine Initiative. And stop exporting our breakthroughs while our patients wait. No American should need a passport to get an American treatment. Bring it home. Thank you to Braelyn and her family for their courage in sharing her story. #RightToTry #BringItHome #UnleashProsperity #DCvaxForBraelyn

How can you argue with $NWBO? Look In a 2026 glioblastoma trial, personalized neoantigen-loaded dendritic cells produced up to a 507-fold increase in neoantigen-specific immune responses. All 11 vaccinated patients were alive 12 months after surgery. doi.org/10.1038/s41467-026-7…

❤️ THIS is why we keep fighting! Andrew, I cannot thank you enough for the extraordinary time, research, and dedication you’ve poured into this proposal. You understand something that families like ours know all too well: Accessing a promising treatment is only half the battle. Being able to CONTINUE that treatment is just as important. Braelyn is 19, attending college, and her latest MRI shows NO EVIDENCE OF DISEASE. Yet we must continue traveling across the Atlantic and raising tens of thousands of dollars for each DCVax treatment. No family fighting for their child’s life should have to face these barriers. To see Braelyn’s story helping inspire meaningful proposals to the FDA—and being shared in the British Parliament in the SAME WEEK—is almost surreal! My deepest hope is that the doors we’re fighting to open for Braelyn will remain open for every patient who comes after her. Thank you, Andrew, for standing with us and turning compassion into action. ❤️🙏🇺🇸🇬🇧 Please read Andrew’s proposal and add your voice to the FDA’s public comment process!
$NWBO #DCVax #DCVaxForBraelyn #RareCancer #RareDisease #Immunotherapy #PatientAdvocacy #GBM 🧬 𝗧𝗵𝗲 𝗗𝗖𝗩𝗮𝘅 𝗽𝗿𝗼𝗽𝗼𝘀𝗮𝗹 𝗶𝘀 𝗻𝗼𝘄 𝗼𝗻 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗿𝗲𝗰𝗼𝗿𝗱. A 19-year-old was in college when she began DCVax-L in London. Treatment had started. Her family was still raising money for the next dose. Her mother's account stayed with me. Underneath it is one question: 𝗛𝗼𝘄 𝗱𝗼𝗲𝘀 𝗮 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘀𝘁𝗮𝗿𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗸𝗲𝗲𝗽 𝗴𝗲𝘁𝘁𝗶𝗻𝗴 𝗶𝘁? On November 6, my 21-page proposal became part of the public record for the FDA's Rare Disease Framework Initiative. I filed it as a physician and patient advocate, independent of Northwest Biotherapeutics. Both treatments start with the patient's own dendritic cells, the cells that teach T cells what to recognize. DCVax-L introduces them to material from the patient's tumor in the lab. DCVax-Direct is injected into a lesion so they meet the tumor there. Same cells, two ways to show them the target. Rare cancers come with no playbook for getting a treatment like this and keeping it. The proposal asks FDA to write one, using 𝗗𝗖𝗩𝗮𝘅-𝗟 𝗮𝗻𝗱 𝗗𝗖𝗩𝗮𝘅-𝗗𝗶𝗿𝗲𝗰𝘁 as the working example. 𝗧𝗵𝗲 𝗽𝗿𝗼𝗽𝗼𝘀𝗮𝗹 𝗮𝘀𝗸𝘀 𝗙𝗗𝗔 𝗳𝗼𝗿 𝘁𝗵𝗿𝗲𝗲 𝘁𝗵𝗶𝗻𝗴𝘀, 𝗶𝗻 𝘄𝗿𝗶𝘁𝗶𝗻𝗴: 1. What the evidence supports for each treatment. 2. Who must arrange to preserve tumor tissue before surgery. 3. Who is responsible for supply and follow-up, so a family knows whom to call when the next dose is due. Plain answers, on paper, so the next family is not guessing. 📄 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰 𝗳𝗶𝗹𝗶𝗻𝗴 regulations.gov/comment/FDA-… 📖 𝗢𝗽𝗲𝗻 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗼𝗽𝗼𝘀𝗮𝗹 · 𝟮𝟭 𝗽𝗮𝗴𝗲𝘀 · 𝟱𝟮 𝘀𝗼𝘂𝗿𝗰𝗲𝘀 mirrulations.s3.amazonaws.co… 𝗪𝗵𝗮𝘁 𝗱𝗼 𝘆𝗼𝘂 𝘄𝗶𝘀𝗵 𝘀𝗼𝗺𝗲𝗼𝗻𝗲 𝗵𝗮𝗱 𝘁𝗼𝗹𝗱 𝘆𝗼𝘂𝗿 𝗳𝗮𝗺𝗶𝗹𝘆 𝘀𝗼𝗼𝗻𝗲𝗿? FDA is taking public comments through 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟭𝟭, 𝟮𝟬𝟮𝟲. You do not need to be a doctor or a lawyer. A few sentences in your own words count: the barrier your family hit, what it cost the person you love, and the one thing you want FDA to change. To stand behind this proposal, cite 𝗙𝗗𝗔-𝟮𝟬𝟮𝟲-𝗡-𝟭𝟮𝟮𝟭𝟰-𝟬𝟬𝟯𝟵. No family should be raising money for the next dose while their child is mid-treatment. 𝗧𝗲𝗹𝗹 𝗙𝗗𝗔. ✍️ 𝗔𝗱𝗱 𝘆𝗼𝘂𝗿 𝘃𝗼𝗶𝗰𝗲 𝘁𝗼 𝘁𝗵𝗲 𝗙𝗗𝗔 𝗱𝗼𝗰𝗸𝗲𝘁 regulations.gov/commenton/FD… 🎥 𝗧𝗵𝗮𝘁 𝟭𝟵-𝘆𝗲𝗮𝗿-𝗼𝗹𝗱 𝗵𝗮𝘀 𝗮 𝗻𝗮𝗺𝗲. On Wednesday, Braelyn Hollensbe sat in the gallery of the House of Commons while an MP asked the Government to help get this treatment into widespread use, and the First Secretary of State replied that the Prime Minister has taken a personal interest. One Parliament has asked the question out loud. The FDA docket is where the rest of us ask it. @FDA @ReaganUdall @RareDiseases @NBTStweets @HollensbeAmanda @mfhugo1 @ThomasOwenMcCa1 @peter_brit @greta @DrOzCMS @DrOz @MelDMann @AlMusella @MHRAgovuk

🇬🇧❤️ WHAT AN INCREDIBLE WAY TO END AN EXTRAORDINARY WEEK IN LONDON! Today, Braelyn received her 5th DCVax treatment with the wonderful Professor Keyoumars Ashkan at King’s College Hospital! Prof. Ashkan was absolutely thrilled about the extraordinary week Braelyn has had in London. And apparently, word travels FAST! He already knew that Braelyn’s story had been shared in the House of Commons during Prime Minister’s Questions! 🇬🇧 But my favorite moment came when I mentioned Braelyn’s latest MRI, which showed NO EVIDENCE OF DISEASE. I had mailed him a hard copy and wanted to make sure he’d received it. His response? “I’VE SEEN IT! THE ENTIRE UK HAS SEEN IT!” 😂❤️ I just LOVE this man! We had sent him and his wonderful assistant our “Because Gray Matter Matters” t-shirts after our last visit, but looking at these pictures, I think I may have seriously overestimated Prof. Ashkan’s shirt size! 😂 This brilliant, compassionate neurosurgeon has played such an important role in helping Braelyn access DCVax-L, and we will forever be grateful for his dedication to patients battling brain cancer. From the halls of Parliament to another precious dose of Braelyn’s personalized cancer vaccine, what an unforgettable week! Thank you, Professor Ashkan, for everything you do for Braelyn and so many other patients. You are truly extraordinary! ❤️🙏 #DCVaxForBrarlyn #BrainCancer #BraelynsFight #DCvax

#NWBO Northwest Biotherapeutics getting a massive shout-out in the UK Parliament today. Surely this will get approved as a therapy by MHRA now it is confirmed that Andy Burnham is taking a personal interest. I am thinking about buying a little bit more - I have tipped NWBO as one of my two highest conviction trades.

Eventful events and memorable moments, by @ascarbs andrewscarborough.substack.c…

It was so lovely to finally meet @HollensbeBrae and her mum, @HollensbeAmanda, yesterday. Diagnosed with GBM in 2023 at just 16, Braelyn has travelled all the way from the US to London for her fifth dose of DCVax-L.

Global chief medical officer for @SwissRe Dr John Schoonbee explains why the second largest reinsurance company in the world cannot afford to ignore insulin resistance and why they are hosting an international conference on nutrition. In my practice I estimate more than 50% of our NHS workload is a result of a poor quality diet

So @drjenunwin and I have a different glycaemic response to the same food. In part because Jen’s insulin works better than mine We only know this through wearing a continuous glucose monitor 👍
Two people can eat the exact same meal and get very different blood sugar responses. When researchers continuously tracked glucose in hundreds of people eating identical standardized meals, the responses varied widely from person to person, and one person could spike more from bananas than from cookies while another showed the reverse. Those differences were tied to each person's gut bacteria, sleep, activity and other traits, and in a smaller follow-up trial, diets tailored to each person's own responses lowered their after-meal glucose. This is one reason I'm such an advocate for continuous glucose monitors. General food lists can only go so far, and a CGM shows how a person's own body handles a specific meal. If someone wants to know how well they tolerate carbohydrate, their own glucose response tells them more than a food's general reputation.